EPTIFIBATIDE (ep-ti-fib'a-tide) Integrilin Classifications: cardiovascular agent; antithrombotic agent; antiplatelet antibody; glycoprotein iib/iiia inhibitor Prototype: Abciximab Pregnancy Category: B |
0.75 mg/mL, 2 mg/mL injection
Binds to the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor sites of platelets.
Inhibits platelet aggregation by preventing fibrinogen, von Willebrand's factor, and other molecules from adhering to GPIIb/IIIa receptor sites on platelets.
Treatment of acute coronary syndromes (unstable angina, non-Q-wave MI) and patients undergoing percutaneous coronary interventions (PCIs).
Hypersensitivity to eptifibatide; active bleeding; GI or GU bleeding within 6 weeks; thrombocytopenia; recent major surgery or trauma; intracranial neoplasm, intracranial bleeding within 6 mo; concurrent administration of another GPIIb/IIIa receptor inhibitor (e.g., abciximab); renal dialysis; severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg), aneurysm.
Hypersensitivity to related compounds (e.g., abciximab, tirofiban, lamifiban); concurrent administration of other anticoagulants; pregnancy (category B), lactation. Safety and effectiveness in children are not established.
Acute Coronary Syndromes (ACS) Adult: IV 180 mcg/kg initial bolus followed by 2 mcg/kg/min until hospital discharge or up to 72 h PCI in Patients with ACS Adult: IV 180 mcg/kg initial bolus followed by 0.5 mcg/kg/min for 2024 h after end of procedure PCI in Patients without ACS Adult: IV 135 mcg/kg initial bolus followed by 0.5 mcg/kg/min for 2024 h after end of procedure |
Intravenous PREPARE: Direct: Give undiluted. ADMINISTER: Direct: Give bolus doses IV push over 12. Continuous: Start continuous infusion immediately following bolus dose. Give undiluted directly from the 100-mL vial (at a rate based on patient's weight) using a vented infusion set. May be given in the same IV line with NS or D5/NS (either solution may contain up to 60 mEq KCl). |
Assessment & Drug Effects